Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma.

ABSTRACT: A comprehensive description of genomic alterations in lung squamous cell carcinoma (lung SCC) has recently been reported, enabling the identification of genomic events that contribute to the oncogenesis of this disease. In lung SCC, one of the most frequently altered receptor tyrosine kinase families is the fibroblast growth factor receptor (FGFR) family, with amplification or mutation observed in all four family members. Here, we describe the oncogenic nature of mutations observed in FGFR2 and FGFR3, each of which are observed in 3% of samples, for a mutation rate of 6% across both genes. Using cell culture and xenograft models, we show that several of these mutations drive cellular transformation. Transformation can be reversed by small-molecule FGFR inhibitors currently being developed

SUBMITTER: Liao RG 

PROVIDER: S-EPMC3749739 | biostudies-literature | 2013 Aug

REPOSITORIES: biostudies-literature